Neuer Schub für Immuntherapien
Welcome to the Hudecek Lab – The home of CAR T
Our research
We are developing novel personalized immune-based cancer treatments that are free from chemotherapy.
Our approach
We are equipping T cells (white blood cells) with a biosensor (chimeric antigen receptor, CAR) to help them detect and eliminate cancer cells.
Latest publications
Luu, M, Binder, K, Hartmann, S et al. (2021)
Transcription factor c-Rel mediates communication between commensal bacteria and mucosal lymphocytes.
J Leukoc Biol.; 1- 7.
Go to publication
Luu, M, Visekruna, A (2021)
Microbial metabolites: novel therapeutic tools for boosting cancer therapies.
Trends in Cell Biology, Volume 31, Issue 11.
Go to publication
Jetani, H, Navarro-Bailón, A, Maucheret, M et al. (2021)
Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia (AML).
Blood 2021.
Go to publication
See more
Luu, M, Riester, Z, Baldrich, A et al. (2021)
Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer.
Nat Commun 12, 4077.
Go to publication
Prommersberger, S, Reiser, M, Beckmann, J et al. (2021)
CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma.
Gene Ther 28, 560–571.
Go to publication
Da Vià, M.C., Dietrich, O., Truger, M. et al. (2021)
Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma.
Nat Med 27, 616–619.
Go to publication
Prommersberger S, Hudecek M, Nerreter T. (2020)
Antibody-Based CAR T Cells Produced by Lentiviral Transduction.
Curr Protoc Immunol. Mar;128(1):e93.
Go to publication
VeranstaltungskalenderÜbersicht
No events today.
Contact person
Univ.-Prof. Dr. med.
Michael Hudecek
Director and Research Group Leader Translational CAR-T Research Program